Model-based Versus Traditional Warfarin Dosing in Children
NCT02475863 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45
Last updated 2015-06-22
Summary
This study compares the clinical effectiveness of a new algorithm (model-based warfarin dosing) with standard practice (doctor's own judgement and intuition) designed to determine the most appropriate anticoagulant dose of warfarin in children after congenital heart surgery.
Conditions
- Congenital Heart Defects
Interventions
- DEVICE
-
Warfarin Dosing Aid
A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
- OTHER
-
Standard Practice
Warfarin dose adjustments according to standard unit protocol
Sponsors & Collaborators
-
University Hospitals, Leicester
collaborator OTHER -
De Montfort University
lead OTHER
Principal Investigators
-
Hussain Mulla, PhD · Univesity Hospitals Leicester NHS Trust
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 1 Day
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-08-31
- Primary Completion
- 2016-08-31
- Completion
- 2018-01-31
More Related Trials
-
Enoxaparin in Children With Asymptomatic Venous Thrombosis After Pediatric Cardiac Surgery
NCT01474902 ·Status: WITHDRAWN ·Phase: PHASE3
-
Thrombin Generation in Neonates
NCT00165906 ·Status: COMPLETED
-
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
NCT04767113 ·Status: COMPLETED ·Phase: NA
-
Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
NCT02103114 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
NCT02981472 ·Status: COMPLETED ·Phase: PHASE2
-
Safer Warfarin Treatment
NCT01042067 ·Status: SUSPENDED
-
A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
NCT05536791 ·Status: WITHDRAWN
-
Pharmacogenetic Dosage Algorithm for Acenocoumarol
NCT03015025 ·Status: COMPLETED
-
Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age
NCT02223260 ·Status: COMPLETED ·Phase: PHASE2
-
Bivalirudin as a Procedural Anticoagulant in Pediatrics
NCT00503126 ·Status: COMPLETED ·Phase: PHASE2
-
Anti Vitamin K Therapeutic Education
NCT01587053 ·Status: TERMINATED
-
The Association of Warfarin Dosage and Plasma Enantiomer Concentration With the Gene Polymorphisms of CYP and VKOR
NCT00247702 ·Status: UNKNOWN ·Phase: NA
-
Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose
NCT02486666 ·Status: UNKNOWN ·Phase: PHASE3
-
Oral Anticoagulant Therapy for Venous Thrombosis - SCOR in Thrombosis
NCT00005684 ·Status: COMPLETED
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
NCT07250763 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease
NCT05643651 ·Status: RECRUITING ·Phase: PHASE4
-
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching
NCT03483181 ·Status: UNKNOWN
-
Individual Dose Adjustment of Low-molecular-weight-heparin by Thromodynamics Test.
NCT04710732 ·Status: TERMINATED ·Phase: PHASE4
-
Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age
NCT01773174 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464 ·Status: COMPLETED ·Phase: NA
-
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
NCT05900388 ·Status: NOT_YET_RECRUITING
-
A Study in the United Sates That Looks at the Safety and Effectiveness of Pradaxa Pellets in Children Aged 3 Months to Less Than 12 Years Who Need Treatment of a Blood Clot or Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot
NCT05966740 ·Status: TERMINATED
-
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
NCT06278051 ·Status: COMPLETED
-
Pharmacogenetic Study of Warfarin Dose-Response: a Prospective Trial
NCT00654823 ·Status: UNKNOWN